Response
To the Editor:
We appreciate Dr. Gibot's comments. The assay we employed was commercially available at the time we conducted our study. 1 The studies of soluble triggering receptor expressed on myeloid cells-1 (or STREM-1) as a diagnostic marker of infection highlight the problems with using assays that are often expensive and nonreproducible in place of other methods (eg, quantitative cultures of the lower respiratory tract) to diagnose infections like ventilator-associated pneumonia. These problems include variances in the available assays and their components (eg, antibodies, reagents), and the lack of validation of such assays under clinically relevant conditions. Given the fact that only commercially available assays would be used clinically in the future, we suggest that any new assay be validated against proven clinical methods prior to being accepted as a standard for the diagnosis of ventilator-associated pneumonia.
